BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28417914)

  • 1. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.
    Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML
    Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
    Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
    Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
    J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).
    Li L; Yu H; Schumacher F; Casey G; Witte JS
    Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
    Wolk A; Mantzoros CS; Andersson SO; Bergström R; Signorello LB; Lagiou P; Adami HO; Trichopoulos D
    J Natl Cancer Inst; 1998 Jun; 90(12):911-5. PubMed ID: 9637140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.
    Young NJ; Metcalfe C; Gunnell D; Rowlands MA; Lane JA; Gilbert R; Avery KN; Davis M; Neal DE; Hamdy FC; Donovan J; Martin RM; Holly JM
    Cancer Causes Control; 2012 Jun; 23(6):907-17. PubMed ID: 22527168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.
    Roddam AW; Allen NE; Appleby P; Key TJ; Ferrucci L; Carter HB; Metter EJ; Chen C; Weiss NS; Fitzpatrick A; Hsing AW; Lacey JV; Helzlsouer K; Rinaldi S; Riboli E; Kaaks R; Janssen JA; Wildhagen MF; Schröder FH; Platz EA; Pollak M; Giovannucci E; Schaefer C; Quesenberry CP; Vogelman JH; Severi G; English DR; Giles GG; Stattin P; Hallmans G; Johansson M; Chan JM; Gann P; Oliver SE; Holly JM; Donovan J; Meyer F; Bairati I; Galan P
    Ann Intern Med; 2008 Oct; 149(7):461-71, W83-8. PubMed ID: 18838726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis.
    Boonen S; Mohan S; Dequeker J; Aerssens J; Vanderschueren D; Verbeke G; Broos P; Bouillon R; Baylink DJ
    J Bone Miner Res; 1999 Dec; 14(12):2150-8. PubMed ID: 10620075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
    Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
    J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
    Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
    J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
    Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
    Spitz MR; Barnett MJ; Goodman GE; Thornquist MD; Wu X; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1413-8. PubMed ID: 12433720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-3, and risk of colorectal cancer: a nested case-control study in the Japan Collaborative Cohort study.
    Suzuki S; Kojima M; Tokudome S; Suzuki K; Ozasa K; Ito Y; Inaba Y; Tajima K; Nakachi K; Watanabe Y; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():45-9. PubMed ID: 20553081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.